Hosted on MSN

Karyopharm targets $1B peak U.S. revenue in myelofibrosis as Phase 3 SENTRY enrollment nears completion

CEO Richard Paulson announced that the Phase 3 SENTRY trial in JAKi-naïve myelofibrosis patients "has passed its prespecified futility analysis and continues as planned without modifications." Paulson ...
Seeking Alpha

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

Co-primary Endpoint Changed to Absolute Total Symptom Score (Abs-TSS) from Total Symptom Score Improvement of ≥ 50% (TSS50) Following Alignment with the FDA Spleen Volume Response Rate ≥ 35% (SVR35) ...
Seeking Alpha

Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis

NEWTON, Mass., Sept. 10, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has completed ...